83 related articles for article (PubMed ID: 9079753)
1. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
2. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
[TBL] [Abstract][Full Text] [Related]
3. Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis.
García-Tello A; Angulo JC; Andrés G; Ramón de Fata F; Sánchez-Chapado M; López JI
Actas Urol Esp; 2014 Oct; 38(8):506-14. PubMed ID: 24702909
[TBL] [Abstract][Full Text] [Related]
4. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.
Fukawa T; Ono M; Matsuo T; Uehara H; Miki T; Nakamura Y; Kanayama HO; Katagiri T
Cancer Res; 2012 Nov; 72(22):5867-77. PubMed ID: 23019224
[TBL] [Abstract][Full Text] [Related]
5. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
6. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
Ronkainen H; Hirvikoski P; Kauppila S; Vaarala MH
Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
[TBL] [Abstract][Full Text] [Related]
7. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
8. Expression of AEG-1 and p53 and their clinicopathological significance in malignant lesions of renal cell carcinomas: a microarray study.
Erdem H; Oktay M; Yildirim U; Uzunlar AK; Kayikci MA
Pol J Pathol; 2013 Apr; 64(1):28-32. PubMed ID: 23625597
[TBL] [Abstract][Full Text] [Related]
9. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
10. Selected morphologic features influencing the prognosis of conventional renal cell carcinomas co-expressing P53 and MDM2.
Hejnold M; Dyduch G; Białas M; Demczuk S; Ryś J; Szopiński T; Chłosta P; Okoń K
Pol J Pathol; 2014 Mar; 65(1):29-33. PubMed ID: 25119006
[TBL] [Abstract][Full Text] [Related]
11. The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis.
Knezović Florijan M; Ozretić P; Bujak M; Pezzè L; Ciribilli Y; Kaštelan Ž; Slade N; Hudolin T
Urol Oncol; 2019 Sep; 37(9):578.e1-578.e10. PubMed ID: 30948335
[TBL] [Abstract][Full Text] [Related]
12. P53 and survivin expression in renal cell carcinoma.
Radovanović M; Petrović M; Šantrić V; Milojević B; Zubelić A; Isaković A
Urol Ann; 2023; 15(2):186-190. PubMed ID: 37304521
[TBL] [Abstract][Full Text] [Related]
13. Novel Expression of Thymine Dimers in Renal Cell Carcinoma, Demonstrated through Immunohistochemistry.
Novacescu D; Cut TG; Cumpanas AA; Bratosin F; Ceausu RA; Raica M
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359193
[TBL] [Abstract][Full Text] [Related]
14. Re-expression of the p53 Gene by Inhibiting the Mdm-2 Receptor in Wild-type p53 Tumors for the Treatment of Glioblastoma: A Mini Review.
Ahmed SI; Bareeqa SB; Samar SS
Cureus; 2018 Jul; 10(7):e3034. PubMed ID: 30254823
[TBL] [Abstract][Full Text] [Related]
15. A Call for Explainer/Tutorial Articles and Changes to Manuscript Submission and Review at MDM and MDM P&P.
Zikmund-Fisher BJ
Med Decis Making; 2020 Oct; 40(7):859-861. PubMed ID: 33081577
[No Abstract] [Full Text] [Related]
16. A Call for Explainer/Tutorial Articles and Changes to Manuscript Submission and Review at MDM and MDM P&P.
Zikmund-Fisher BJ
MDM Policy Pract; 2020; 5(2):2381468320966542. PubMed ID: 33178889
[No Abstract] [Full Text] [Related]
17. Introducing
Schwartz AJ
MDM Policy Pract; 2016; 1(1):2381468316661547. PubMed ID: 30288404
[No Abstract] [Full Text] [Related]
18. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA_0074027 participates in cell proliferation, apoptosis and metastasis of colorectal cancer cells through regulation of miR‑525‑3p.
Xiong G; Zhang J; Zhang Y; Pang X; Wang B; Zhang Y
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760126
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
